• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

九种粪便免疫化学检测用于结直肠癌检测的比较评估。

Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer.

机构信息

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center , Germany.

出版信息

Acta Oncol. 2013 Nov;52(8):1667-75. doi: 10.3109/0284186X.2013.789141. Epub 2013 Apr 25.

DOI:10.3109/0284186X.2013.789141
PMID:23617541
Abstract

BACKGROUND

Faecal immunochemical tests (FITs) for haemoglobin are increasingly used for non-invasive screening for colorectal cancer (CRC) but large scale comparative studies of different FITs for detection of CRC, overall and by stage, are sparse. We aimed to determine and compare performance of different FITs for the detection of CRC, and to assess their stage-specific sensitivities.

MATERIAL AND METHODS

We assessed sensitivity, specificity and their corresponding 95% confidence intervals for six qualitative FITs among 74 CRC cases (59% stage I or II cancers) and 1480 controls free of colorectal neoplasm. Overall and stage-specific receiver operating characteristic curves were derived for three quantitative FITs. The areas under the curves (AUCs) were calculated and compared.

RESULTS

Pairs of overall sensitivity and specificity of the qualitative FITs ranged from 66% and 96% to 92% and 62%, respectively. For the three quantitative tests, AUCs ranged from 0.90 to 0.92, with sensitivities ranging from 80% to 87% at cut-offs yielding 90% specificity. AUCs ranged from 0.85 to 0.92, 0.94 to 0.96, and 0.86 to 0.93 for stage I, stage II and advanced stages (stage III and IV) cancers, respectively. At a specificity of 90%, the tests detected 65%-85% of stage I cancers.

CONCLUSION

The diagnostic performance of FITs regarding detection of CRC is promising, even though the pre-defined cut-offs of some of the qualitative FITs need to be adjusted to limit false-positive rates in screening setting. At cut-off levels yielding 90% specificity, the quantitative tests detected the vast majority of CRCs, even at early stages.

摘要

背景

粪便免疫化学检测(FIT)用于血红蛋白检测,逐渐成为结直肠癌(CRC)非侵入性筛查的手段,但关于不同 FIT 检测 CRC 的大规模对比研究较少,包括整体和各期 CRC 的情况。我们旨在确定并比较不同 FIT 检测 CRC 的性能,并评估其各期 CRC 的特异性敏感性。

材料和方法

我们评估了 6 种定性 FIT 在 74 例 CRC 病例(59%为 I 期或 II 期癌症)和 1480 例无结直肠肿瘤对照中的敏感性、特异性及其相应的 95%置信区间。为 3 种定量 FIT 绘制了总体和各期特异性的受试者工作特征曲线,并计算和比较了曲线下面积(AUC)。

结果

定性 FIT 的总体敏感性和特异性的配对范围分别为 66%和 96%至 92%和 62%。对于三种定量检测,AUC 范围从 0.90 到 0.92,在特异性为 90%的情况下,截止值为 80%到 87%,灵敏度范围为 80%到 87%。AUC 范围为 0.85 到 0.92、0.94 到 0.96 和 0.86 到 0.93,分别用于 I 期、II 期和晚期(III 期和 IV 期)癌症。在特异性为 90%的情况下,这些检测可检出 65%-85%的 I 期癌症。

结论

即使一些定性 FIT 的预定义截止值需要调整以限制筛查中的假阳性率,FIT 检测 CRC 的诊断性能仍有前景。在特异性为 90%的情况下,定量检测可检测到绝大多数 CRC,即使是早期阶段。

相似文献

1
Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer.九种粪便免疫化学检测用于结直肠癌检测的比较评估。
Acta Oncol. 2013 Nov;52(8):1667-75. doi: 10.3109/0284186X.2013.789141. Epub 2013 Apr 25.
2
Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.在一项 2235 名筛查结肠镜参与者的头对头比较中,粪便免疫化学试验检测血红蛋白的诊断性能优于愈创木脂粪便隐血试验。
Eur J Cancer. 2013 Sep;49(14):3049-54. doi: 10.1016/j.ejca.2013.04.023. Epub 2013 May 22.
3
Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening.调整良好的定性免疫化学粪便潜血试验可能是一种有前途的替代方法,可用于廉价、高质量的结直肠癌筛查。
Eur J Cancer Prev. 2013 Jul;22(4):305-10. doi: 10.1097/CEJ.0b013e32835b6991.
4
Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers.更高的粪便免疫化学检测截断值:较低的阳性率,但对早期结直肠癌仍有可接受的检出率。
Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):272-80. doi: 10.1158/1055-9965.EPI-10-0848. Epub 2010 Dec 6.
5
A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.基于人群的免疫化学粪便潜血试验用于结直肠癌筛查的比较。
Gastroenterology. 2013 May;144(5):918-25. doi: 10.1053/j.gastro.2013.01.042. Epub 2013 Feb 1.
6
Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.粪便免疫化学试验检测结直肠癌的阶段特异性敏感性:系统评价和荟萃分析。
Am J Gastroenterol. 2020 Jan;115(1):56-69. doi: 10.14309/ajg.0000000000000465.
7
Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm.定量和定性粪便免疫化学检测血红蛋白在结直肠肿瘤人群筛查中的预测能力。
Eur J Cancer Prev. 2014 Jan;23(1):27-34. doi: 10.1097/CEJ.0b013e328364f229.
8
Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?粪便免疫化学检测的前瞻性横断面研究:获得结直肠癌同等敏感性的性别特异性临界值?
BMC Gastroenterol. 2014 Dec 21;14:217. doi: 10.1186/s12876-014-0217-7.
9
Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.用于检测结直肠肿瘤的自动化粪便 DNA 检测的临床性能。
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1313-8. doi: 10.1016/j.cgh.2013.04.023. Epub 2013 Apr 29.
10
Performance improvements of stool-based screening tests.粪便检测筛查试验的性能改善。
Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):479-92. doi: 10.1016/j.bpg.2010.03.009.

引用本文的文献

1
Fecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers.粪便免疫化学检测在筛查出患有多个进展性腺瘤的参与者方面,比筛查出T1期结直肠癌更为有效。
Cancers (Basel). 2021 Feb 5;13(4):644. doi: 10.3390/cancers13040644.
2
Colorectal cancer screening: Assessment of , , and as blood markers in faecal immunochemical test negative subjects.结直肠癌筛查:评估粪便免疫化学检测阴性受试者中[具体指标未给出]、[具体指标未给出]、[具体指标未给出]和[具体指标未给出]作为血液标志物的情况。
J Adv Res. 2020 Mar 3;24:99-107. doi: 10.1016/j.jare.2020.03.001. eCollection 2020 Jul.
3
Combination of Different Fecal Immunochemical Tests in Colorectal Cancer Screening: Any Gain in Diagnostic Performance?
不同粪便免疫化学检测联合用于结直肠癌筛查:诊断性能有提高吗?
Cancers (Basel). 2019 Jan 20;11(1):120. doi: 10.3390/cancers11010120.
4
Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening.直接比较十种用于结直肠癌筛查的粪便免疫化学试验定量检测血红蛋白稳定性的比较。
Clin Transl Gastroenterol. 2018 Jul 6;9(7):168. doi: 10.1038/s41424-018-0035-2.
5
Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence.基于粪便的结直肠癌检测:现有证据概述
Curr Gastroenterol Rep. 2017 Aug;19(8):39. doi: 10.1007/s11894-017-0579-4.
6
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.粪便免疫化学检测筛查结直肠肿瘤的建议:美国结直肠癌多学会特别工作组的共识声明
Am J Gastroenterol. 2017 Jan;112(1):37-53. doi: 10.1038/ajg.2016.492. Epub 2016 Oct 18.
7
Diagnostic work-up of patients presenting in primary care with lower abdominal symptoms: which faecal test and triage strategy should be used?基层医疗中出现下腹部症状患者的诊断检查:应采用哪种粪便检测和分诊策略?
BMC Med. 2016 Sep 26;14(1):139. doi: 10.1186/s12916-016-0694-3.
8
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).人群结直肠癌筛查意味着使用粪便免疫化学试验检测血红蛋白(FIT)进行 FIT:结直肠癌筛查的过去、现在和未来。
Gut Liver. 2014 Mar;8(2):117-30. doi: 10.5009/gnl.2014.8.2.117. Epub 2014 Mar 11.